Pfizer (PFE) reported Q4 FY2023 earnings of $0.10 per share (versus $1.14 per share in Q4 FY2022), much better than analysts’ consensus estimate of -$0.18 per share.
The company’s quarterly revenues amounted to $14.249 bln (-41.3% y/y), slightly missing analysts’ consensus estimate of $14.369 bln.
The company also issued guidance for FY2024, seeing EPS of $2.05-2.25 versus analysts’ consensus estimate of $2.27 and revenues of $58.5-61.5 bln versus analysts’ consensus estimate of $60.46 bln.
PFE rose to $27.58 (+0.36%) in pre-market trading.